Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franck Boccara

Showing results (51-60 of 138) with videos related to

Pageof 14
Sort By:
International Journal of Cardiology|March 16, 2011
C-reactive protein and transesophageal echocardiographic markers of thromboembolism in patients with atrial fibrillationStéphane Ederhy, Emanuele Di Angelantonio, Ghislaine Dufaitre, et al.
Current Pharmaceutical Design|August 7, 2010
Adipose tissue as a target of HIV-1 antiretroviral drugs. Potential consequences on metabolic regulationsMartine Caron-Debarle, Franck Boccara, Claire Lagathu, et al.
Antiviral Therapy|June 3, 2010
HIV protease inhibitors activate the adipocyte renin angiotensin systemFranck Boccara, Martine Auclair, Ariel Cohen, et al.
Atherosclerosis|January 3, 2016
LMNA mutations resulting in lipodystrophy and HIV protease inhibitors trigger vascular smooth muscle cell senescence and calcification: Role of ZMPSTE24 downregulationPauline Afonso, Martine Auclair, Franck Boccara, et al.
AIDS (London, England)|January 13, 2022
Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension periodFranck Boccara, Bruno Caramelli, Alexandra Calmy, et al.
AIDS (London, England)|April 20, 2010
Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general populationSylvie Lang, Murielle Mary-Krause, Laurent Cotte, et al.
British Journal of Clinical Pharmacology|December 17, 2008
Relationship between HIV protease inhibitors and QTc interval duration in HIV-infected patients: a cross-sectional studyBeny Charbit, Arnaud Rosier, Diane Bollens, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|February 9, 2013
Peroxisome proliferator-activated receptor-γ mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin systemMartine Auclair, Corinne Vigouroux, Franck Boccara, et al.
American Heart Journal|December 17, 2019
Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristicsFranck Boccara, Princy Kumar, Bruno Caramelli, et al.
Atherosclerosis Plus|January 16, 2023
Burden of cardiovascular disease in a large contemporary cohort of patients with heterozygous familial hypercholesterolemiaJean Ferrières, Michel Farnier, Eric Bruckert, et al.
Pageof 14

Showing results (51-60 of 138) with videos related to

Sort By:
Pageof 14
International Journal of Cardiology|March 16, 2011
C-reactive protein and transesophageal echocardiographic markers of thromboembolism in patients with atrial fibrillationStéphane Ederhy, Emanuele Di Angelantonio, Ghislaine Dufaitre, et al.
Current Pharmaceutical Design|August 7, 2010
Adipose tissue as a target of HIV-1 antiretroviral drugs. Potential consequences on metabolic regulationsMartine Caron-Debarle, Franck Boccara, Claire Lagathu, et al.
Antiviral Therapy|June 3, 2010
HIV protease inhibitors activate the adipocyte renin angiotensin systemFranck Boccara, Martine Auclair, Ariel Cohen, et al.
Atherosclerosis|January 3, 2016
LMNA mutations resulting in lipodystrophy and HIV protease inhibitors trigger vascular smooth muscle cell senescence and calcification: Role of ZMPSTE24 downregulationPauline Afonso, Martine Auclair, Franck Boccara, et al.
AIDS (London, England)|January 13, 2022
Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension periodFranck Boccara, Bruno Caramelli, Alexandra Calmy, et al.
AIDS (London, England)|April 20, 2010
Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general populationSylvie Lang, Murielle Mary-Krause, Laurent Cotte, et al.
British Journal of Clinical Pharmacology|December 17, 2008
Relationship between HIV protease inhibitors and QTc interval duration in HIV-infected patients: a cross-sectional studyBeny Charbit, Arnaud Rosier, Diane Bollens, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|February 9, 2013
Peroxisome proliferator-activated receptor-γ mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin systemMartine Auclair, Corinne Vigouroux, Franck Boccara, et al.
American Heart Journal|December 17, 2019
Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristicsFranck Boccara, Princy Kumar, Bruno Caramelli, et al.
Atherosclerosis Plus|January 16, 2023
Burden of cardiovascular disease in a large contemporary cohort of patients with heterozygous familial hypercholesterolemiaJean Ferrières, Michel Farnier, Eric Bruckert, et al.
Pageof 14